Approval · Notice of Compliance 252 · 2003
PROCYTOX: Notice of Compliance 252
Issued October 17, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 252
- Date
- October 17, 2003
- Company
- Baxter CorporationMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the product monograph
- Therapeutic class
- Antineoplastic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PROCYTOX | Not yet assigned | — |
Medicinal ingredients
- CYCLOPHOSPHAMIDE 25 MG per TAB
- CYCLOPHOSPHAMIDE 50 MG per TAB
- CYCLOPHOSPHAMIDE 200 MG per VIAL
- CYCLOPHOSPHAMIDE 500 MG per VIAL
- CYCLOPHOSPHAMIDE 1,000 MG per VIAL
- CYCLOPHOSPHAMIDE 2,000 MG per VIAL